Abstract:Tumor angiogenesis is important in the growth and metastasis of malignant tumors. In our previous study, we demonstrated that an arginine-arginine-leucine (RRL) peptide is a tumor endothelial cell-specific binding sequence that may be used as a molecular probe for the imaging of malignant tumors in vivo. The aim of the present study was to further explore the characteristics of I-131-RRL by biodistribution tests, and to estimate the radiation dosimetry of I-131-RRL for humans using mice data. The RRL peptide was radiolabeled with I-131 by a chloramine-T (CH-T) method. The radiolabeling efficiency and radiochemical purity were then characterized in vitro. I-131-RRL was injected intravenously into B16 xenograft-bearing Kunming mice. Biodistribution analysis and in vivo imaging were performed periodically. The radiation dosimetry in humans was calculated according to the organ distribution and the standard medical internal radiation dose (MIRD) method in mice. All data were analyzed by statistical and MIRDOSE 3.1 software. The labeling efficiency of I-131-RRL reached 70.0 +/- 2.91% (n=5), and the radiochemical purity exceeded 95% following purification. In mice bearing B16 xenografts, I-131-RRL rapidly cleared from the blood and predominantly accumulated in the kidneys, the stomach and the tumor tissue. The specific uptake of I-131-RRL in the tumor increased over time and was significantly higher than that of the other organs, 24-72 h following injection (P<0.05). The ratio of tumor-to-skeletal muscle (T/SM) tissue exceeded 4.75, and the ratio of the tumor-to-blood (T/B) tissue peaked at 3.36. In the single-photon emission computed tomography (SPECT) imaging of Kunming mice bearing B16 xenografts, the tumors were clearly identifiable at 6 h, and significant uptake was evident 24-72 h following administration of I-131-RRL. The effective dose for the adult male dosimetric model was estimated to be 0.0293 mSv/MBq. Higher absorbed doses were estimated for the stomach (0.102 mGy/MBq), the small intestines (0.0699 mGy/MBq), the kidneys (0.0611 mGy/MBq) and the liver (0.055 mGy/MBq). These results highlight the potential of I-131-RRL as a ligand for the SPECT imaging of tumors. Administration of I-131-RRL led to a reasonable radiation dose burden and was safe for human use.

Screening, Radiolabeling and Biodistribution of Lung Tumor-targeting Peptide YC11 by in vivo Phage Display

Radiolabeling and Biodistribution of a Nasopharyngeal Carcinoma-Targeting Peptide Identified by in Vivo Phage Display.

Studies on distribution and imaging of 131I-labelled RGD peptide in mice bearing tumors

Identification of a peptide binding to cancer antigen Kita‐kyushu lung cancer antigen 1 from a phage‐display library

Comparing two TAG-72 binding peptides previously identified by phage display as potential imaging agents.

Radiolabeling of Filamentous Phage Peptide Library with ~(99m)tc and Its Biodistribution in Normal Mice

99Mtc-Labeled RGD-BBN Peptide for Small-Animal SPECT/CT of Lung Carcinoma.

Screening Tumor-Targeting Bacteriophage Particles by Pre-Clearing Phage Display

A novel radioiodinated peptide of arginine-arginine-leucine(RRL)for biodistribution and tumor angiogenic endothelium imaging

125I–F56 Peptide As Radioanalysis Agent Targeting VEGFR1 in Mice Xenografted with Human Gastric Tumor

Identification of a Glypican-3 Binding Peptide From a Phage-Displayed Peptide Library for PET Imaging of Hepatocellular Carcinoma

Identification of a High Affinity TAG-72 Binding Peptide by Phage Display Selection

Lung Cancer-Targeting Peptides with Multi-subtype Indication for Combinational Drug Delivery and Molecular Imaging

Development of a new positron emission tomography tracer for targeting tumor angiogenesis: synthesis, small animal imaging, and radiation dosimetry

Evaluation of 111 In-DOTA-F56 peptide targeting VEGFR1 for potential non- invasive gastric cancer xenografted tumor mice Micro-SPECT imaging

Molecular Imaging and Preclinical Studies of Radiolabeled Long-Term RGD Peptides in U-87 MG Tumor-Bearing Mice

Multiple-tumor binding specificity and high tumor uptake of monoclonal antibody 3H11

131)I Labeling and Bioactivity Evaluation of a Novel RGD Dimer Targeted to Integrin Αvβ3 Receptor

Tumor Angiogenesis Imaging Agent: Biodistribution of 131I-YG5 and 131I-Boc-yg5

Astatine-211 labelled a small molecule peptide: specific cell killing in vitro and targeted therapy in a nude-mouse model

Validation study of 131I-RRL: Assessment of biodistribution, SPECT imaging and radiation dosimetry in mice